Subscribe to RSS
DOI: 10.1055/s-2008-1027989
© Georg Thieme Verlag KG Stuttgart · New York
Gastrointestinale Onkologie – Therapieupdate 2008 / 2009
Gastrointestinal Oncology – Therapy Update 2008 / 2009Publication History
Manuskript eingetroffen: 22.10.2008
Manuskript akzeptiert: 9.11.2008
Publication Date:
06 March 2009 (online)

Zusammenfassung
Die Therapie gastrointestinaler Malignome wird zunehmend komplexer und ist immer neuen Aspekten aktueller klinischer Studien unterworfen. Die Steuerungsgruppe der AGIO hat sich zum Ziel gemacht, über die derzeitig gültigen Behandlungsrichtlinien gastrointestinaler Tumoren hinausgehend die aktuelle Studienlage 2008 zeitgerecht zusammenzufassen, um neueste Behandlungoptionen für die wesentlichen gastrointestinalen Tumoren darzustellen. In dieser Übersichtsarbeit werden daher aktuelle Daten aus klinischen Studien zum Ösophagus-, Magen-, Pankreas, Cholangio- und Leberzellkarzinom sowie für kolorektalen Karzinome, neuroendokrine Tumoren und Lymphome des Gastrointestinaltrakts dargestellt. Dabei wurden sowohl aktuelle Kombinationen mit zielgerichteten „Targeted Therapies” als auch erste prädiktive Biomarker als Grundlage für die Therapieentscheidung berücksichtigt.
Abstract
As a consequence of recent studies the treatment of gastrointestinal cancers has become challenging and is undergoing constant changes on the basis of the results of new trials. The steering committee of the working group on gastrointestinal cancers of the Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten has decided to summarise and present recent updates of the current treatment guidelines and recommendations for the most relevant gastrointestinal malignancies. In this review we have included recent findings from large trials on esophageal, gastric, pancreatic, cholangiocellular and liver cancers, as well as colorectal cancers, neuroendocrine tumours and lymphomas. This includes an update on the combination with novel targeted agents and the introduction of potential predictive biomarkers in the selection of the appropriate treatment strategy.
Schlüsselwörter
kolorektales Karzinom - Magenkarzinom - Gastro-entero-pankreatische Tumoren - Onkologie - Tumortherapie
Key words
colorectal cancer - stomach cancer - gastro-entero-pancreatic tumours - oncology - tumour therapy
Literatur
- 1
Siewert J R, Ott K.
Are squamous and adenocarcinomas of the esophagus the same disease?.
Semin Radiat Oncol.
2007;
17
38-44
Reference Ris Wihthout Link
- 2
Groth S S, Whitson B A, Li Z. et al .
Determination of the ideal number of lymph nodes to examine to optimize survival in
patients with esophageal carcinoma: Data from the surveillance epidemiology and end
results database.
J Clin Oncol.
2008;
26
A4528
Reference Ris Wihthout Link
- 3
Pech O, May A, Gossner L. et al .
Curative endoscopic therapy in patients with early esophageal squamous-cell carcinoma
or high-grade intraepithelial neoplasia.
Endoscopy.
2007;
39
30-35
Reference Ris Wihthout Link
- 4
Ishii N, Tsukamoto M, Izuka Y. et al .
Endoscopic Submucosal Dissection Is a Safe and Effective Treatment for Superficial
Esophageal Cancer. First Results in a Primary Hospital.
Gastrointestinal Endoscopy.
2008;
67
A184
Reference Ris Wihthout Link
- 5
Deprez P H, Yeung R C, Aouattah T. et al .
Prospective Randomized Comparison Between EMR and ESD for Endoscopic Removal of Superficial
Esophageal Cancer.
Gastrointestinal Endoscopy.
2008;
67
A187
Reference Ris Wihthout Link
- 6
Shimada H, Nabeya Y, Matsubara H. et al .
Prediction of lymph node status in patients with superficial esophageal carcinoma:
analysis of 160 surgically resected cancers.
Am J Surg.
2006;
191
250-254
Reference Ris Wihthout Link
- 7
Konda V J, Chennat J S, Ross A S. et al .
Low Rate of Invasive Cancer in Patients Undergoing Mucosectomy for Barrett’s Esophagus
(BE) and High Grade Dysplasia (HGD) Or Intramucosal Carcinoma (IMC).
Gastrointestinal Endoscopy.
2008;
67
A76
Reference Ris Wihthout Link
- 8
Oyama T, Kitamura Y, Hotta K.
Long Term Prognosis of ESD for the Superficial Esophageal Squamous Cell Carcinoma.
Gastrointestinal Endoscopy.
2008;
67
A182
Reference Ris Wihthout Link
- 9
Gockel I, Hansen T, Sultanov F S. et al .
High Prevalence of Lymph Node Metastases in pT1 Esophageal Cancer: Is Local Therapy
Justified?.
Gastroenterology.
2008;
134
A-904
Reference Ris Wihthout Link
- 10
Igaki H, Kato H, Ando N. et al .
A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil
versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma
of the thoracic esophagus (JCOG 9907).
J Clin Oncol.
2008;
26
A4510
Reference Ris Wihthout Link
- 11
Tepper J, Krasna M J, Niedzwiecki D. et al .
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy,
and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
J Clin Oncol.
2008;
26
1086-1092
Reference Ris Wihthout Link
- 12
Gebski V, Burmeister B, Smithers B M. et al .
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal
carcinoma: a meta-analysis.
Lancet Oncol.
2007;
8
226-234
Reference Ris Wihthout Link
- 13
Boige V, Pignon J, Saint-Aubert B. et al .
Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin
(P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC
ACCORD07-FFCD 9703 trial.
J Clin Oncol.
2007;
25
A4510
Reference Ris Wihthout Link
- 14
Cunningham D, Allum W H, Stenning S P. et al .
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
N Engl J Med.
2006;
355
11-20
Reference Ris Wihthout Link
- 15
Di Fiore F, Lecleire S, Rigal O. et al .
Predictive factors of survival in patients treated with definitive chemoradiotherapy
for squamous cell esophageal carcinoma.
World J Gastroenterol.
2006;
12
4185-4190
Reference Ris Wihthout Link
- 16
Lordick F, Ott K, Krause B J. et al .
PET to assess early metabolic response and to guide treatment of adenocarcinoma of
the oesophagogastric junction: the MUNICON phase II trial.
Lancet Oncol.
2007;
8
797-805
Reference Ris Wihthout Link
- 17
Lecleire S, Di Fiore F, Antonietti M. et al .
Double Stenting of Esophagus and Airways in Patients with Locally Advanced Esophageal
Cancer: Feasibility, Efficacy and Complications.
Gastrointestinal Endoscopy.
2006;
63
A123
Reference Ris Wihthout Link
- 18
Chadha K S, Schiff M D, Sitrin M D. et al .
Analysis of Clinical Outcomes of Esophageal Stent Placement for Palliation of Malignant
Dysphagia.
Gastrointestinal Endoscopy.
2008;
67
A188
Reference Ris Wihthout Link
- 19
Chen Y K, Schefter T, Newman F.
Esophageal Cancer Patients Undergoing External Beam Radiation After Placement of Self-Expandable
Metal Stents (SEMS): Is There a Risk of Radiation Dose Enhancement?.
Gastrointestinal Endoscopy.
2008;
67
A184
Reference Ris Wihthout Link
- 20
Van Cutsem E, Moiseyenko V M, Tjulandin S. et al .
V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared
with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:
a report of the V 325 Study Group.
J Clin Oncol.
2006;
24
4991-4997
Reference Ris Wihthout Link
- 21
Allum W H, Fogarty P J, Stenning J P. et al .
Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative
chemotherapy in resectable esophageal cancer.
Proc ASCO GI Symposium.
2008;
Abstract #9
Reference Ris Wihthout Link
- 22
Lutz M P, Wilke H, Wagener D J. et al .
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA),
or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II
trial 40 953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal
Group and the Arbeitsgemeinschaft Internistische Onkologie.
J Clin Oncol.
2007;
25
2580-2585
Reference Ris Wihthout Link
- 23
Ridwelski K, Fahlke J, Kettner E. et al .
Docetaxel-cisplatin versus 5-fluorouracil-leukovorin-cisplatin as first-line treatment
for locally advanced or metastatic gastric cancer: Preliminary results of a phase
III study.
J Clin Oncol.
2008;
26
A4512
Reference Ris Wihthout Link
- 24
Neoptolemos J P, Stocken D D, Friess H. et al .
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic
cancer.
N Engl J Med.
2004;
350
1200-1210
Reference Ris Wihthout Link
- 25
Oettle H, Post S, Neuhaus P. et al .
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent
resection of pancreatic cancer: a randomized controlled trial.
JAMA.
2007;
297
267-277
Reference Ris Wihthout Link
- 26
Neuhaus P, Riess H, Post S. et al .
CONKO-001: Final results of the randomised, prospective, multicenter phase III trial
of adjuvant chemotherapy with gemicitabine vs. observation in patients with resected
pancreatic cancer.
J Clin Oncol.
2008;
26
A4504
Reference Ris Wihthout Link
- 27
Van Laethem J, Van Cutsem E, Hammel P. et al .
Adjuvant chemotherapy alone versus chemoradiationafter curative resection for pancreatic
cancer: feasibility resultsof a randomised EORTC/FFCD/GERCOR phase II/III study (40
013 / 2201 / 00 304).
J Clin Oncol.
2008;
26
A4514
Reference Ris Wihthout Link
- 28
Picozzi V J, Abrams R A, Traverso L W. et al .
ACOSOG Z 05 031: Report on a multicenter, phase II trial for adjuvant therapy of resected
pancreatic cancer using cisplatin, 5-FU, and alpha-interferon.
J Clin Oncol.
2008;
26
A4505
Reference Ris Wihthout Link
- 29
Moore M J, Goldstein D, Hamm J. et al .
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced
pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical
Trials Group.
J Clin Oncol.
2007;
25
1960-1966
Reference Ris Wihthout Link
- 30
Heinemann V, Boeck S, Hinke A. et al .
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination
chemotherapy applied in advanced pancreatic cancer.
BMC Cancer.
2008;
8
82
Reference Ris Wihthout Link
- 31
Vervenne W, Bennouna J, Humblet Y. et al .
A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to
evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine
(G) in patients (pts) with metastatic pancreatic cancer.
J Clin Oncol.
2008;
26
A4507
Reference Ris Wihthout Link
- 32
Kindler H L, Gangadhar T, Karrison T. et al .
Final analysis of a randomized phase II study of bevacizumab and gemcitabine plus
cetuximab or erlotinib in patients with advanced pancreatic cancer.
J Clin Oncol.
2008;
26
A4502
Reference Ris Wihthout Link
- 33
Tuinmann G, Müller L, Hossfeld D. et al .
A randomised phase II study of gemcitabine versus mitomycin C versus gemcitabine/mitomycin
C in patients with advanced pancreatic cancer.
J Clin Oncol.
2008;
26
A15658
Reference Ris Wihthout Link
- 34
Pelzer U, Kubica K, Stieler J. et al .
A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final
results of the CONKO 003 study.
J Clin Oncol.
2008;
26
A4508
Reference Ris Wihthout Link
- 35
Mitry E, Dahan L, Ychou M. et al .
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic
cancer: Preliminary results of a randomized phase III trial (FFCD 0301).
J Clin Oncol.
2008;
26
A4513
Reference Ris Wihthout Link
- 36
Loehrer P J, Powell M E, Cardenes H R. et al .
A randomized phase III study of gemcitabine in combination with radiation therapy
versus gemcitabine alone in patients with localized, unresectable pancreatic cancer:
E 4201.
J Clin Oncol.
2008;
26
A4506
Reference Ris Wihthout Link
- 37
Chauffert B, Mornex F, Bonnetain F. et al .
Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional
5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced
non metastatic pancreatic cancer: A FFCD-SFRO study.
J Clin Oncol.
2006;
24
A4008
Reference Ris Wihthout Link
- 38
Javle M M, Okazaki T, Evans D B. et al .
Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis
in patients receiving neoadjuvant therapy for pancreatic cancer.
J Clin Oncol.
2008;
26
A4501
Reference Ris Wihthout Link
- 39
Marelli L, Stigliano R, Triantos C. et al .
Transarterial therapy for hepatocellular carcinoma: which technique is more effective?
A systematic review of cohort and randomized studies.
Cardiovasc Intervent Radiol.
2007;
30
6-25
Reference Ris Wihthout Link
- 40
Hanks B A, Suhocki P V, DeLong D M. et al .
The efficacy and tolerability of transarterial chemo-embolization (TACE) compared
with transarterial embolization (TAE) for patients with unresectable hepatocellular
carcinoma (HCC).
J Clin Oncol.
2008;
26
A4595
Reference Ris Wihthout Link
- 41
Vit A, De Pauli F, Sponza M. et al .
Transarterial chemoembolization (TACE) with doxorubicin eluting beads (DEB) for the
treatment of hepatocellular carcinoma (HCC).
J Clin Oncol.
2008;
26
A4598
Reference Ris Wihthout Link
- 42
Graf H, Jüngst C, Straub G. et al .
Chemoembolization Combined with Pravastatin Improves Survival in Patients with Hepatocellular
Carcinoma.
Digestion.
2008;
78
34-38
Reference Ris Wihthout Link
- 43
Llovet J M, Ricci S, Mazzaferro V. et al .
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med.
2008;
359
378-390
Reference Ris Wihthout Link
- 44
Cheng A, Kang Y, Chen Z. et al .
Randomized phase III trial of sorafenib versus placebo in Asian patients with advance
hepatocellular carcinoma.
J Clin Oncol.
2008;
26
A4509
Reference Ris Wihthout Link
- 45
Raoul J, Santoro A, Beaugrand M. et al .
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma
according to ECOG performance status: A subanalysis from the SHARP trial.
J Clin Oncol.
2008;
26
A4587
Reference Ris Wihthout Link
- 46
Sherman M, Mazzaferro V, Amadori D. et al .
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma
and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial.
J Clin Oncol.
2008;
26
A4584
Reference Ris Wihthout Link
- 47
Craxi A, Porta C, Sangiovanni A. et al .
Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma:
A sub-analysis from the SHARP trial.
J Clin Oncol.
2008;
26
A15591
Reference Ris Wihthout Link
- 48
Abou-Alfa G K, Amadori D, Santoro A. et al .
Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma
(HCC) and Child-Pugh B (CPB) cirrhosis?.
J Clin Oncol.
2008;
26
A4518
Reference Ris Wihthout Link
- 49
Dollinger M M, Lautenschläger C, Lesske J. et al .
Thymostimulin versus placebo for treatment of advanced hepatocellular carcinoma: A
randomized, controlled, double-blind, multicenter study.
J Clin Oncol.
2008;
26
A4519
Reference Ris Wihthout Link
- 50
Kim H, Lee S, Bae S. et al .
Phase II study of gemcitabine and oxaliplatin as first-line chemotherapy in patients
with inoperable biliary tract cancer.
J Clin Oncol.
2008;
26
A15536
Reference Ris Wihthout Link
- 51
Gerber D, Dietrich D, Koeberle D. et al .
Clinical benefit and quality of life in patients with advanced biliary tract cancer
receiving gemcitabine plus capecitabine: Results from a multicenter phase II trial
(SAKK 44 / 02).
J Clin Oncol.
2008;
26
A15531
Reference Ris Wihthout Link
- 52
Grünberger B, Schueller J, Kaczirek K. et al .
Efficacy results of cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with
advanced or metastatic cholangiocarcinoma: A single center phase II study.
J Clin Oncol.
2008;
26
A4586
Reference Ris Wihthout Link
- 53
Holen K D, Mahoney M R, LoConte N K. et al .
Efficacy report of a multicenter phase II trial testing a biologic-only combination
of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary
cancer: A Phase II Consortium study.
J Clin Oncol.
2008;
26
A4522
Reference Ris Wihthout Link
- 54
Dealis C, Bertolini F, Malavasi N. et al .
A phase II trial of sorafenib in patients with advanced cholangiocarcinoma.
J Clin Oncol.
2008;
26
A4590
Reference Ris Wihthout Link
- 55
Ribic C M, Sargent D J, Moore M J. et al .
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based
adjuvant chemotherapy for colon cancer.
N Engl J Med.
2003;
349
247-257
Reference Ris Wihthout Link
- 56
Sargent D J, Marsoni S, Thibodeau S N. et al .
Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of
benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled
molecular reanalysis of randomized chemotherapy trials.
J Clin Oncol.
2008;
26
A4008
Reference Ris Wihthout Link
- 57
Reinacher-Schick A C, Kubicka S, Freier W. et al .
Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev)
or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized
phase II study of the AIO Colorectal Study Group (AIO trial 0604).
J Clin Oncol.
2008;
26
A4030
Reference Ris Wihthout Link
- 58
Heinemann V, Fischer von Weikersthal L, Vehling-Kaiser U. et al .
Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first
line treatment of patients with metastatic colorectal cancer (mCRC): A study of the
german AIO CRC study group.
J Clin Oncol.
2008;
26
A4033
Reference Ris Wihthout Link
- 59
Artale S, Sartore-Bianchi A, Veronese S M. et al .
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.
J Clin Oncol.
2008;
26
4217-4219
Reference Ris Wihthout Link
- 60
Amado R G, Wolf M, Peeters M. et al .
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal
cancer.
J Clin Oncol.
2008;
26
1626-1634
Reference Ris Wihthout Link
- 61
Bokemeyer C, Bondarenko I, Hartmann J T. et al .
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal
cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience.
J Clin Oncol.
2008;
26
A4000
Reference Ris Wihthout Link
- 62
Van Cutsem E, Lang I, D’haens G. et al .
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal
cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience.
J Clin Oncol.
2008;
26
A2
Reference Ris Wihthout Link
- 63
Ince W L, Jubb A M, Holden S N. et al .
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
J Natl Cancer Inst.
2005;
97
981-989
Reference Ris Wihthout Link
- 64
Tejpar S, Peeters M, Humblet Y. et al .
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with
irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan
(q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary
data).
J Clin Oncol.
2008;
26
A4001
Reference Ris Wihthout Link
- 65
Loupakis F, Pollina L, Stasi I. et al .
Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in
primary tumors as predictors of activity of cetuximab plus irinotecan treatment.
J Clin Oncol.
2008;
26
A4003
Reference Ris Wihthout Link
- 66
4 ENETS Guidelines.
Neuroendocrinology.
2006;
84
155-215
Reference Ris Wihthout Link
- 67
5 ENETS Guidelines.
Neuroendocrinology.
2008;
87
8-39
Reference Ris Wihthout Link
- 68
Rindi G, Klöppel G, Alhman H. et al .
European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine
tumors: a consensus proposal including a grading system.
Virchows Arch.
2006;
449
395-401
Reference Ris Wihthout Link
- 69
Rindi G, Klöppel G, Couvelard A. et al .
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including
a grading system.
Virchows Arch.
2007;
451
757-762
Reference Ris Wihthout Link
- 70
Pape U F, Jann H, Müller-Nordhorn J. et al .
Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic
neuroendocrine tumors.
Cancer.
2008;
113
256-265
Reference Ris Wihthout Link
- 71
Hörsch D, Prasad V, Baum R P.
Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with
progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin
receptor targeting peptides.
J Clin Oncol.
2008;
26
A4517
Reference Ris Wihthout Link
- 72
Kwekkeboom D J, Herder W W, Kam B L. et al .
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate:
toxicity, efficacy, and survival.
J Clin Oncol.
2008;
26
2124-2123
Reference Ris Wihthout Link
- 73
Kennedy A S, Dezarn W A, McNeillie de P. et al .
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres:
early results in 148 patients.
Am J Clin Oncol.
2008;
31
271-279
Reference Ris Wihthout Link
- 74
Rhee T K, Lewandowski R J, Liu D M. et al .
90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results
from a multi-institutional experience.
Ann Surg.
2008;
247
1029-1035
Reference Ris Wihthout Link
- 75
King J, Glenn D, Quinn R. et al .
Radioactive microspheres in liver metastases from neuroendocrine cancer (NETML).
J Clin Oncol.
2008;
26
A15541
Reference Ris Wihthout Link
- 76
Yao J C, Phan A T, Chang D Z. et al .
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade
neuroendocrine tumors: results of a phase II study.
J Clin Oncol.
2008;
26
4311-4318
Reference Ris Wihthout Link
- 77
Yao J C, Lombard-Bohas C, Baudin E. et al .
A phase II trial of daily oral RAD001(Everolimus) in patients with metastatic pancreatic
neuroendocrine tumors after failure of cytotoxic chemotherapy.
ESMO.
2008;
Abstract 508PD
Reference Ris Wihthout Link
- 78
Kulke M H, Lenz H J, Meropol N J. et al .
Activity of sunitinib in patients with advanced neuroendocrine tumors.
J Clin Oncol.
2008;
26
3403-3410
Reference Ris Wihthout Link
- 79
Yao J C, Phan A, Hoff P M. et al .
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random
assignment phase II study of depot octreotide with bevacizumab and pegylated interferon
alpha-2b.
J Clin Oncol.
2008;
26
1316-1323
Reference Ris Wihthout Link
- 80
Hobday J, Rubin J, Holen K. et al .
MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine
tumors (NET): A Phase II Consortium (P2C) study.
J Clin Oncol.
2007;
25
A4504
Reference Ris Wihthout Link
- 81
Pavel M E, Bartel C, Heuck F. et al .
Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis
inhibitor PTK787 / ZK 222 584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas
(NEC).
J Clin Oncol.
2008;
26
A1468
Reference Ris Wihthout Link
- 82
Duran I, Kortmansky J, Singh D. et al .
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine
carcinomas.
Br J Cancer.
2006;
95
1148-1154
Reference Ris Wihthout Link
- 83
Sung M W, Kvols L, Jacob G. et al .
Phase II proof-of-concept study of atiprimod in patients with advanced low- to intermediate-grade
neuroendocrine carcinoma.
J Clin Oncol.
2008;
26
A4611
Reference Ris Wihthout Link
- 84
Varker K A, Campbell J, Shah M H.
Phase II study of thalidomide in patients with metastatic carcinoid and islet cell
tumors.
Cancer Chemother Pharmacol.
2008;
61
661-668
Reference Ris Wihthout Link
- 85
Kulke M H, Bergsland E K, Ryan D P. et al .
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine
tumors.
J Clin Oncol.
2006;
24
3555-3561
Reference Ris Wihthout Link
- 86
Dogliotti L, Brizzi M P, Ferrero A. et al .
Phase II trial of continuous/metronomic 5-fluorouracil infusion plus long acting Octreotide
in advanced neuroendocrine carcinoma.
J Clin Oncol.
2007;
256
A15003
Reference Ris Wihthout Link
- 87
Ekeblad S, Sundin A, Janson E T. et al .
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine
tumors.
Clin Cancer Res.
2007;
13
2986-2991
Reference Ris Wihthout Link
- 88
Kulke M H, Stuart K, Enzinger P C. et al .
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine
Tumors.
J Clin Oncol.
2006;
24
401-406
Reference Ris Wihthout Link
- 89
Kulke M H, Stuart K, Earle C C. et al .
A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine
tumors.
J Clin Oncol.
2008;
26
A4044
Reference Ris Wihthout Link
- 90
Strosberg J R, Choi J, Gardner N. et al .
First-line treatment of metastastic pancreatic endocrine carcinomas with capecitabine
and temozolomide.
J Clin Oncol.
2008;
26
A4612
Reference Ris Wihthout Link
- 91
Bajetta E, Catena L, Procopio G. et al .
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade
and high-grade neuroendocrine tumours ?.
Cancer Chemother Pharmacol.
2007;
59
637-642
Reference Ris Wihthout Link
- 92
Venook A P, Ko A H, Tempero M A. et al .
Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine
tumors.
J Clin Oncol.
2008;
26
A15545
Reference Ris Wihthout Link
- 93
Kunz P L, Kuo T, Kaiser H L. et al .
A phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable
neuroendocrine tumors: preliminary results.
J Clin Oncol.
2008;
26
A15502
Reference Ris Wihthout Link
- 94
Capelle L G, Vries A C, Looman C W. et al .
Epidemiology of Gastric MALT Lymphoma: A Long-Term Nationwide Study in the Netherlands.
Gastroenterology.
2008;
134
A618
Reference Ris Wihthout Link
- 95
Fischbach de W, Dietrich C G, Al-Taie O H. et al .
Value of Routine Capsule Endoscopy in the Strategy of Patients with Primary Gastric
Non-Hodgkin’s Lymphoma.
Gastroenterology.
2008;
134
A296
Reference Ris Wihthout Link
- 96
Fischbach W, Goebeler M, Schramm S. et al .
Outcome and Quality of Life Favor a Conservative Treatment of Patients with Primary
Gastric NHL’s. Results of a Prospective Randomized Study.
Gastroenterology.
2008;
134
A296
Reference Ris Wihthout Link
- 97
Wündisch T, Dieckhoff P, Gunther A. et al .
10-year follow up of 120 patients with gastric MALT lymphoma after Helicobacter pylori
eradication – Histological residual disease and second cancers.
J Clin Oncol.
2008;
26
A8536
Reference Ris Wihthout Link
- 98
Capelle L G, Vries A C, Looman C W. et al .
High Adenocarcinoma Risk After Diagnosis of Gastric MALT Lymphoma: A Long-Term Nationwide
Study.
Gastroenterology.
2008;
134
A12
Reference Ris Wihthout Link
- 99
Spadaio de P, Pitini V, Toscano G. et al .
Clinical activity of bortezomib in relapsed or refractory gastric marginal zone b-cell
lymphoma of malt type.
J Clin Oncol.
2008;
26
A8567
Reference Ris Wihthout Link
- 100
Salar A, Domingo-Domenech E, Estany C. et al .
First-line treatment with rituximab combined with intravenous or oral fludarabine
for patients with extranodal mucosa associated lymphoid tissue (MALT) lymphoma.
J Clin Oncol.
2008;
26
A8608
Reference Ris Wihthout Link
- 101
Aguiar Bujanda D, Cabrera Suárez M A, Llorca Martínez I. et al .
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for
treatment of primary gastrointestinal B-cell lymphoma.
J Clin Oncol.
2008;
26
A19536
Reference Ris Wihthout Link
Prof. Matthias P. A. Ebert
II. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München
Ismaninger Str. 22
81675 München
Phone: ++ 49/89/41 40 48 72
Fax: ++ 49/89/41 40 22 59
Email: ebertm@gmx.de